CASP3 and B-cell chronic lymphocytic leukemia: Prior to treatment (T0), low caspase-3 activity was identified in the CLL patients compared with the healthy donors; however, one week after treatment commenced, an increase in caspase-3 activity was observed in all of the responder patients (24/30) and an additional increase was observed six months after the commencement of treatment (Fig. 4).